Next New Releases from NCBI BookshelfBurosumab (Crysvita): Indication: For the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older: Reimbursement Recommendation [Internet].Burosumab (Crysvita): Indication: For the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older: Reimbursement Recommendation [Internet].